Integra LifeSciences Holdings Corporation
IART · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,099,870 | $938,201 | $1,681,421 | $1,746,587 |
| - Cash | $232,186 | $217,914 | $239,104 | $246,375 |
| + Debt | $213,509 | $2,013,769 | $2,018,937 | $1,984,563 |
| Enterprise Value | $1,081,193 | $2,734,056 | $3,461,254 | $3,484,775 |
| Revenue | $402,062 | $415,605 | $382,653 | $442,646 |
| % Growth | -3.3% | 8.6% | -13.6% | – |
| Gross Profit | $226,108 | $209,332 | $194,432 | $249,072 |
| % Margin | 56.2% | 50.4% | 50.8% | 56.3% |
| EBITDA | $54,063 | -$472,218 | $25,967 | $79,114 |
| % Margin | 13.4% | -113.6% | 6.8% | 17.9% |
| Net Income | -$5,404 | -$484,073 | -$25,293 | $19,435 |
| % Margin | -1.3% | -116.5% | -6.6% | 4.4% |
| EPS Diluted | -0.07 | -6.33 | -0.33 | 0.25 |
| % Growth | 98.9% | -1,818.2% | -232% | – |
| Operating Cash Flow | $40,906 | $8,919 | -$11,257 | $50,740 |
| Capital Expenditures | -$15,156 | -$20,146 | -$28,920 | -$39,553 |
| Free Cash Flow | $25,750 | -$11,227 | -$40,177 | $11,187 |